

Publikationen 2019-2023

- 1 Thomssen C, Vetter M, Kantelhardt EJ, Meisner C, Schmidt M, Martin PM, Clatot F, Augustin D, Hanf V, Paepke D, Meinerz W, Hoffmann G, Wiest W, Sweep FCGJ, Schmitt M, Jänicke F, Loibl S, Minckwitz G von, Harbeck N: Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group. *Cancers* 2023;15.
- 2 Bachmann HS, Jung D, Link T, Arnold A, Kantelhardt E, Thomssen C, Wimberger P, Vetter M, Kuhlmann JD: FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer. *Cancers* 2022;14.
- 3 Desalegn Z, Yohannes M, Porsch M, Stückrath K, Anberber E, Santos P, Bauer M, Addissie A, Bekuretsion Y, Assefa M, Worku Y, Taylor L, Abebe T, Kantelhardt EJ, Vetter M: Intrinsic subtypes in Ethiopian breast cancer patient. *Breast Cancer Res Treat* 2022;196:495–504.
- 4 Erber R, Angeloni M, Stöhr R, Lux MP, Ulbrich-Gebauer D, Pelz E, Bankfalvi A, Schmid KW, Walter RFH, Vetter M, Thomssen C, Mayr D, Klauschen F, Sinn P, Sotlar K, Stering K, Stenzinger A, Wunderle M, Fasching PA, Beckmann MW, Hoffmann O, Kimmig R, Harbeck N, Wuerstlein R, Ferrazzi F, Hartmann A: Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. *Int J Mol Sci* 2022;23.
- 5 Reinhardt K, Stückrath K, Hartung C, Kaufhold S, Uleer C, Hanf V, Lantzsch T, Peschel S, John J, Pöhler M, Bauer M, Bürrig FK, Weigert E, Buchmann J, Kantelhardt EJ, Thomssen C, Vetter M: PIK3CA-mutations in breast cancer. *Breast Cancer Res Treat* 2022;196:483–493.
- 6 Schüler K, Bethmann D, Kaufhold S, Hartung C, Stückrath K, Lantzsch T, Uleer C, Hanf V, Peschel S, John J, Pöhler M, Buchmann J, Bürrig K-F, Weigert E, Thomssen C, Kantelhardt EJ, Vetter M: Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients. *Diagnostics (Basel)* 2022;12.
- 7 Berdiel-Acer M, Maia A, Hristova Z, Borgoni S, Vetter M, Burmester S, Becki C, Michels B, Abnaof K, Binenbaum I, Bethmann D, Chatziioannou A, Hasmann M, Thomssen C, Espinet E, Wiemann S: Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts. *Oncogene* 2021;40:2651–2666.
- 8 Bley N, Schott A, Müller S, Misiak D, Lederer M, Fuchs T, Aßmann C, Glaß M, Ihling C, Sinz A, Pazaitis N, Wickenhauser C, Vetter M, Ungurs O, Strauss H-G, Thomssen C, Hüttelmaier S: IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer. *RNA Biol* 2021;18:391–403.
- 9 Hartung C, Porsch M, Stückrath K, Kaufhold S, Staeger MS, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Pöhler M, Weigert E, Buchmann J, Bürrig K-F, Schüler K, Bethmann D, Große I, Kantelhardt EJ, Thomssen C, Vetter M: Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. *Breast Care (Basel)* 2021;16:637–647.

- 10 Mitra D, Vega-Rubin-de-Celis S, Royla N, Bernhardt S, Wilhelm H, Tarade N, Poschet G, Buettner M, Binenbaum I, Borgoni S, Vetter M, Kantelhardt EJ, Thomssen C, Chatziioannou A, Hell R, Kempa S, Müller-Decker K, Wiemann S: Abrogating GPT2 in triple-negative breast cancer inhibits tumor growth and promotes autophagy. *Int J Cancer* 2021;148:1993–2009.
- 11 Reibold CF, Tariku W, Eber-Schulz P, Getachew S, Addisie A, Unverzagt S, Wienke A, Hauptmann S, Wickenhauser C, Vetter M, Jemal A, Thomssen C, Kantelhardt EJ: Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia. *Breast Care (Basel)* 2021;16:484–490.
- 12 Bauer M, Kantelhardt EJ, Stiewe T, Nist A, Mernberger M, Politt K, Hanf V, Lantsch T, Uleer C, Peschel S, John J, Buchmann J, Weigert E, Bürrig K-F, Wickenhauser C, Thomssen C, Bartel F, Vetter M: Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. *Oncotarget* 2019;10:1975–1992.
- 13 Berchtold E, Vetter M, Gündert M, Csaba G, Fathke C, Ulbrich SE, Thomssen C, Zimmer R, Kantelhardt EJ: Comparison of six breast cancer classifiers using qPCR. *Bioinformatics* 2019;35:3412–3420.
- 14 Kuhlmann JD, Bachmann HS, Link T, Wimberger P, Kröber E, Thomssen C, Mallé B, Bethmann D, Vetter M, Kantelhardt EJ: Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer. *Sci Rep* 2019;9:12594.

Buchbeitrag:

1. Kantelhardt EJ, Vetter M, Strauß H-G: Mammakarzinomrezidiv und metastasiertes Mammakarzinom; in Wacker J, Sillem M, Bastert G, Beckmann MW (eds): *Therapiehandbuch Gynäkologie und Geburtshilfe*, 3. Auflage. Berlin, Heidelberg, Springer, 2020, pp 421–437.